Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Combe

Showing results (131-140 of 282) with videos related to

Pageof 29
Sort By:
Joint Bone Spine|December 15, 2021
Impact of multimorbidity on disease modifying antirheumatic drug therapy in early rheumatoid arthritis: Data from the ESPOIR cohortAurélie Beltai, Bernard Combe, Amandine Coffy, et al.
Arthritis Care & Research|August 5, 2015
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III TrialsBernard Combe, Daniel E Furst, Edward C Keystone, et al.
Arthritis Research & Therapy|February 14, 2006
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritisOlivier Meyer, Pascale Nicaise-Roland, Marie Dos Santos, et al.
Annals of the Rheumatic Diseases|March 10, 2012
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET studyPaul Emery, Tore K Kvien, Bernard Combe, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Rheumatology (Oxford, England)|December 25, 2012
Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patientsAdeline Ruyssen-Witrand, Stéphanie Rouanet, Bernard Combe, et al.
Arthritis Research & Therapy|March 22, 2022
Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combinationOlivier Vittecoq, Clément Guillou, Julie Hardouin, et al.
RMD Open|November 5, 2015
Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohortsAna Maria Gherghe, Maxime Dougados, Bernard Combe, et al.
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Pageof 29

Showing results (131-140 of 282) with videos related to

Sort By:
Pageof 29
Joint Bone Spine|December 15, 2021
Impact of multimorbidity on disease modifying antirheumatic drug therapy in early rheumatoid arthritis: Data from the ESPOIR cohortAurélie Beltai, Bernard Combe, Amandine Coffy, et al.
Arthritis Care & Research|August 5, 2015
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III TrialsBernard Combe, Daniel E Furst, Edward C Keystone, et al.
Arthritis Research & Therapy|February 14, 2006
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritisOlivier Meyer, Pascale Nicaise-Roland, Marie Dos Santos, et al.
Annals of the Rheumatic Diseases|March 10, 2012
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET studyPaul Emery, Tore K Kvien, Bernard Combe, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Rheumatology (Oxford, England)|December 25, 2012
Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patientsAdeline Ruyssen-Witrand, Stéphanie Rouanet, Bernard Combe, et al.
Arthritis Research & Therapy|March 22, 2022
Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combinationOlivier Vittecoq, Clément Guillou, Julie Hardouin, et al.
RMD Open|November 5, 2015
Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohortsAna Maria Gherghe, Maxime Dougados, Bernard Combe, et al.
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Pageof 29